GRI Bio (NASDAQ:GRI – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Earnings and Valuation
This table compares GRI Bio and Editas Medicine”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GRI Bio | N/A | N/A | -$11.96 million | ($235.02) | -0.01 |
| Editas Medicine | $32.31 million | 6.65 | -$237.09 million | ($2.38) | -0.92 |
Risk & Volatility
GRI Bio has a beta of -1.38, meaning that its share price is 238% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500.
Institutional & Insider Ownership
34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by company insiders. Comparatively, 1.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares GRI Bio and Editas Medicine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GRI Bio | N/A | -381.74% | -206.45% |
| Editas Medicine | -430.84% | -277.29% | -62.49% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for GRI Bio and Editas Medicine, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GRI Bio | 1 | 0 | 2 | 0 | 2.33 |
| Editas Medicine | 1 | 1 | 2 | 2 | 2.83 |
GRI Bio currently has a consensus target price of $644.00, indicating a potential upside of 25,154.90%. Editas Medicine has a consensus target price of $5.00, indicating a potential upside of 127.27%. Given GRI Bio’s higher probable upside, analysts clearly believe GRI Bio is more favorable than Editas Medicine.
Summary
Editas Medicine beats GRI Bio on 8 of the 13 factors compared between the two stocks.
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
